Bromodomain Containing Protein 4 drugs in development by Therapy Areas, Indications, Stages, MoA, RoA, Molecule Type, and Key Players, 2023

The report also covers products from therapy areas such as Oncology, Respiratory, and Dermatology which include the indications Solid Tumor, Ovarian Cancer, Idiopathic Pulmonary Fibrosis, Dermatitis (Eczema), and Vitiligo. It also reviews key players involved in Bromodomain Containing Protein 4 targeted therapeutics development with respective active and dormant or discontinued products.

The Bromodomain Containing Protein 4 pipeline targets constitutes close to 54 molecules. Out of which, approximately 42 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 2, 10, 13, 2, 21, and 11 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 6, and 6 molecule.

Bromodomain Containing Protein 4 overview

Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. It acts as a regulator of p53/TP53-mediated transcription.

For a complete picture of Bromodomain Containing Protein 4’s drug pipeline, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.